Clinical features and survival analysis of 40 cases of anti-MDA5 antibody-positive dermatomyositis complicated with interstitial lung disease
Background Several studies have shown that patients with anti-MDA5 antibody-positive dermatomyositis (anti-MDA5 antibody + DM) have an increased risk of developing rapid progression of interstitial lung disease (RPILD), which is associated with poor prognosis and high mortality. However, diagnosis a...
Uložené v:
| Vydané v: | Arthritis research & therapy Ročník 27; číslo 1; s. 32 - 14 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
London
BioMed Central
13.02.2025
BioMed Central Ltd BMC |
| Predmet: | |
| ISSN: | 1478-6354, 1478-6362, 1478-6362 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Background
Several studies have shown that patients with anti-MDA5 antibody-positive dermatomyositis (anti-MDA5 antibody + DM) have an increased risk of developing rapid progression of interstitial lung disease (RPILD), which is associated with poor prognosis and high mortality. However, diagnosis and treatment are often delayed due to atypical early clinical features and heterogeneity. Therefore, clinical features should be identified to establish a prognosis model for early identification and intervention, thereby improving the clinical prognosis of patients.
Objectives
The study aimed to investigate the clinical features, risk factors, treatment strategy, and construct a survival prognosis model for anti-MDA5 antibody + DM patients with ILD.
Methods
A total of 40 anti-MDA5 antibody + DM-ILD patients admitted to the Department of Pulmonary and Critical Care Medicine and the Department of Rheumatology and Immunology in the Second Affiliated Hospital of Xi 'an Jiaotong University from September 2018 to May 2022 were retrospectively analyzed. Prognostic factors correlated with overall survival (OS) during hospitalization were identified by multivariate Cox regression analysis, and a nomogram was established. The nomogram was internally validated using C-index and time-dependent (at 1-, 2-, and 3- months) calibration curves with 1000 iterations of bootstrap resampling. Moreover, the optimal truncation values for continuous variables and Kaplan–Meier (K-M) curves were determined, which were used to analyze the difference in survival between groups. Finally, time-dependent decision curve analysis (DCA) was employed to validate the clinical value of the nomogram.
Results
Significant differences were found between the survival group and the non-survival group in terms of age, oxygenation index, extent of lung lesions, diffuse alveolar damage (DAD) and nonspecific interstitial pneumonia (NSIP), and LDH, GLU, CEA, ferritin, CRP levels in serum (
P
< 0.05). Multivariate regression analysis revealed that increased NSIP in high-resolution computed tomography (HRCT) and ALT,LDH,CEA,CRP were risk factors for poor prognosis (
P
< 0.05). A nomogram diagram was constructed according to the final multiple Cox model to predict the 1-, 2-, and 3-month OS. According to ALT, AST, LDH, CEA, and CRP cutoff values, the KM algorithm was used to estimate the survival curve (
P
< 0.05). DCA curves were drawn for the model-dependent variables included treatment style, NSIP, ALT, AST, LDH, CEA, and CRP. This indicated that the nomogram yielded a higher net benefit compared to other single prognostic factors, and the cutoff value grouping model showed better practical application value. Combined treatment with glucocorticoids and immunosuppressants was a protective factor for long-term survival. Survival analysis indicated that patients with anti-MDA5 + DM-ILD could benefit from combined treatment for longer survival.
Conclusions
Anti-MDA5 antibody + DM is prone to interstitial lung disease, poor prognosis, and high mortality. Risk prediction model could help us paying attention to these features which may allow the early identification of high-risk patients and promote timely diagnosis and treatment. |
|---|---|
| AbstractList | Several studies have shown that patients with anti-MDA5 antibody-positive dermatomyositis (anti-MDA5 antibody + DM) have an increased risk of developing rapid progression of interstitial lung disease (RPILD), which is associated with poor prognosis and high mortality. However, diagnosis and treatment are often delayed due to atypical early clinical features and heterogeneity. Therefore, clinical features should be identified to establish a prognosis model for early identification and intervention, thereby improving the clinical prognosis of patients.BACKGROUNDSeveral studies have shown that patients with anti-MDA5 antibody-positive dermatomyositis (anti-MDA5 antibody + DM) have an increased risk of developing rapid progression of interstitial lung disease (RPILD), which is associated with poor prognosis and high mortality. However, diagnosis and treatment are often delayed due to atypical early clinical features and heterogeneity. Therefore, clinical features should be identified to establish a prognosis model for early identification and intervention, thereby improving the clinical prognosis of patients.The study aimed to investigate the clinical features, risk factors, treatment strategy, and construct a survival prognosis model for anti-MDA5 antibody + DM patients with ILD.OBJECTIVESThe study aimed to investigate the clinical features, risk factors, treatment strategy, and construct a survival prognosis model for anti-MDA5 antibody + DM patients with ILD.A total of 40 anti-MDA5 antibody + DM-ILD patients admitted to the Department of Pulmonary and Critical Care Medicine and the Department of Rheumatology and Immunology in the Second Affiliated Hospital of Xi 'an Jiaotong University from September 2018 to May 2022 were retrospectively analyzed. Prognostic factors correlated with overall survival (OS) during hospitalization were identified by multivariate Cox regression analysis, and a nomogram was established. The nomogram was internally validated using C-index and time-dependent (at 1-, 2-, and 3- months) calibration curves with 1000 iterations of bootstrap resampling. Moreover, the optimal truncation values for continuous variables and Kaplan-Meier (K-M) curves were determined, which were used to analyze the difference in survival between groups. Finally, time-dependent decision curve analysis (DCA) was employed to validate the clinical value of the nomogram.METHODSA total of 40 anti-MDA5 antibody + DM-ILD patients admitted to the Department of Pulmonary and Critical Care Medicine and the Department of Rheumatology and Immunology in the Second Affiliated Hospital of Xi 'an Jiaotong University from September 2018 to May 2022 were retrospectively analyzed. Prognostic factors correlated with overall survival (OS) during hospitalization were identified by multivariate Cox regression analysis, and a nomogram was established. The nomogram was internally validated using C-index and time-dependent (at 1-, 2-, and 3- months) calibration curves with 1000 iterations of bootstrap resampling. Moreover, the optimal truncation values for continuous variables and Kaplan-Meier (K-M) curves were determined, which were used to analyze the difference in survival between groups. Finally, time-dependent decision curve analysis (DCA) was employed to validate the clinical value of the nomogram.Significant differences were found between the survival group and the non-survival group in terms of age, oxygenation index, extent of lung lesions, diffuse alveolar damage (DAD) and nonspecific interstitial pneumonia (NSIP), and LDH, GLU, CEA, ferritin, CRP levels in serum (P < 0.05). Multivariate regression analysis revealed that increased NSIP in high-resolution computed tomography (HRCT) and ALT,LDH,CEA,CRP were risk factors for poor prognosis (P < 0.05). A nomogram diagram was constructed according to the final multiple Cox model to predict the 1-, 2-, and 3-month OS. According to ALT, AST, LDH, CEA, and CRP cutoff values, the KM algorithm was used to estimate the survival curve (P < 0.05). DCA curves were drawn for the model-dependent variables included treatment style, NSIP, ALT, AST, LDH, CEA, and CRP. This indicated that the nomogram yielded a higher net benefit compared to other single prognostic factors, and the cutoff value grouping model showed better practical application value. Combined treatment with glucocorticoids and immunosuppressants was a protective factor for long-term survival. Survival analysis indicated that patients with anti-MDA5 + DM-ILD could benefit from combined treatment for longer survival.RESULTSSignificant differences were found between the survival group and the non-survival group in terms of age, oxygenation index, extent of lung lesions, diffuse alveolar damage (DAD) and nonspecific interstitial pneumonia (NSIP), and LDH, GLU, CEA, ferritin, CRP levels in serum (P < 0.05). Multivariate regression analysis revealed that increased NSIP in high-resolution computed tomography (HRCT) and ALT,LDH,CEA,CRP were risk factors for poor prognosis (P < 0.05). A nomogram diagram was constructed according to the final multiple Cox model to predict the 1-, 2-, and 3-month OS. According to ALT, AST, LDH, CEA, and CRP cutoff values, the KM algorithm was used to estimate the survival curve (P < 0.05). DCA curves were drawn for the model-dependent variables included treatment style, NSIP, ALT, AST, LDH, CEA, and CRP. This indicated that the nomogram yielded a higher net benefit compared to other single prognostic factors, and the cutoff value grouping model showed better practical application value. Combined treatment with glucocorticoids and immunosuppressants was a protective factor for long-term survival. Survival analysis indicated that patients with anti-MDA5 + DM-ILD could benefit from combined treatment for longer survival.Anti-MDA5 antibody + DM is prone to interstitial lung disease, poor prognosis, and high mortality. Risk prediction model could help us paying attention to these features which may allow the early identification of high-risk patients and promote timely diagnosis and treatment.CONCLUSIONSAnti-MDA5 antibody + DM is prone to interstitial lung disease, poor prognosis, and high mortality. Risk prediction model could help us paying attention to these features which may allow the early identification of high-risk patients and promote timely diagnosis and treatment. Several studies have shown that patients with anti-MDA5 antibody-positive dermatomyositis (anti-MDA5 antibody + DM) have an increased risk of developing rapid progression of interstitial lung disease (RPILD), which is associated with poor prognosis and high mortality. However, diagnosis and treatment are often delayed due to atypical early clinical features and heterogeneity. Therefore, clinical features should be identified to establish a prognosis model for early identification and intervention, thereby improving the clinical prognosis of patients. The study aimed to investigate the clinical features, risk factors, treatment strategy, and construct a survival prognosis model for anti-MDA5 antibody + DM patients with ILD. A total of 40 anti-MDA5 antibody + DM-ILD patients admitted to the Department of Pulmonary and Critical Care Medicine and the Department of Rheumatology and Immunology in the Second Affiliated Hospital of Xi 'an Jiaotong University from September 2018 to May 2022 were retrospectively analyzed. Prognostic factors correlated with overall survival (OS) during hospitalization were identified by multivariate Cox regression analysis, and a nomogram was established. The nomogram was internally validated using C-index and time-dependent (at 1-, 2-, and 3- months) calibration curves with 1000 iterations of bootstrap resampling. Moreover, the optimal truncation values for continuous variables and Kaplan-Meier (K-M) curves were determined, which were used to analyze the difference in survival between groups. Finally, time-dependent decision curve analysis (DCA) was employed to validate the clinical value of the nomogram. Significant differences were found between the survival group and the non-survival group in terms of age, oxygenation index, extent of lung lesions, diffuse alveolar damage (DAD) and nonspecific interstitial pneumonia (NSIP), and LDH, GLU, CEA, ferritin, CRP levels in serum (P < 0.05). Multivariate regression analysis revealed that increased NSIP in high-resolution computed tomography (HRCT) and ALT,LDH,CEA,CRP were risk factors for poor prognosis (P < 0.05). A nomogram diagram was constructed according to the final multiple Cox model to predict the 1-, 2-, and 3-month OS. According to ALT, AST, LDH, CEA, and CRP cutoff values, the KM algorithm was used to estimate the survival curve (P < 0.05). DCA curves were drawn for the model-dependent variables included treatment style, NSIP, ALT, AST, LDH, CEA, and CRP. This indicated that the nomogram yielded a higher net benefit compared to other single prognostic factors, and the cutoff value grouping model showed better practical application value. Combined treatment with glucocorticoids and immunosuppressants was a protective factor for long-term survival. Survival analysis indicated that patients with anti-MDA5 + DM-ILD could benefit from combined treatment for longer survival. Anti-MDA5 antibody + DM is prone to interstitial lung disease, poor prognosis, and high mortality. Risk prediction model could help us paying attention to these features which may allow the early identification of high-risk patients and promote timely diagnosis and treatment. Background Several studies have shown that patients with anti-MDA5 antibody-positive dermatomyositis (anti-MDA5 antibody + DM) have an increased risk of developing rapid progression of interstitial lung disease (RPILD), which is associated with poor prognosis and high mortality. However, diagnosis and treatment are often delayed due to atypical early clinical features and heterogeneity. Therefore, clinical features should be identified to establish a prognosis model for early identification and intervention, thereby improving the clinical prognosis of patients. Objectives The study aimed to investigate the clinical features, risk factors, treatment strategy, and construct a survival prognosis model for anti-MDA5 antibody + DM patients with ILD. Methods A total of 40 anti-MDA5 antibody + DM-ILD patients admitted to the Department of Pulmonary and Critical Care Medicine and the Department of Rheumatology and Immunology in the Second Affiliated Hospital of Xi 'an Jiaotong University from September 2018 to May 2022 were retrospectively analyzed. Prognostic factors correlated with overall survival (OS) during hospitalization were identified by multivariate Cox regression analysis, and a nomogram was established. The nomogram was internally validated using C-index and time-dependent (at 1-, 2-, and 3- months) calibration curves with 1000 iterations of bootstrap resampling. Moreover, the optimal truncation values for continuous variables and Kaplan-Meier (K-M) curves were determined, which were used to analyze the difference in survival between groups. Finally, time-dependent decision curve analysis (DCA) was employed to validate the clinical value of the nomogram. Results Significant differences were found between the survival group and the non-survival group in terms of age, oxygenation index, extent of lung lesions, diffuse alveolar damage (DAD) and nonspecific interstitial pneumonia (NSIP), and LDH, GLU, CEA, ferritin, CRP levels in serum (P < 0.05). Multivariate regression analysis revealed that increased NSIP in high-resolution computed tomography (HRCT) and ALT,LDH,CEA,CRP were risk factors for poor prognosis (P < 0.05). A nomogram diagram was constructed according to the final multiple Cox model to predict the 1-, 2-, and 3-month OS. According to ALT, AST, LDH, CEA, and CRP cutoff values, the KM algorithm was used to estimate the survival curve (P < 0.05). DCA curves were drawn for the model-dependent variables included treatment style, NSIP, ALT, AST, LDH, CEA, and CRP. This indicated that the nomogram yielded a higher net benefit compared to other single prognostic factors, and the cutoff value grouping model showed better practical application value. Combined treatment with glucocorticoids and immunosuppressants was a protective factor for long-term survival. Survival analysis indicated that patients with anti-MDA5 + DM-ILD could benefit from combined treatment for longer survival. Conclusions Anti-MDA5 antibody + DM is prone to interstitial lung disease, poor prognosis, and high mortality. Risk prediction model could help us paying attention to these features which may allow the early identification of high-risk patients and promote timely diagnosis and treatment. Keywords: Anti-MDA5 antibody, Dermatomyositis, Interstitial lung disease, Prognostic factors Abstract Background Several studies have shown that patients with anti-MDA5 antibody-positive dermatomyositis (anti-MDA5 antibody + DM) have an increased risk of developing rapid progression of interstitial lung disease (RPILD), which is associated with poor prognosis and high mortality. However, diagnosis and treatment are often delayed due to atypical early clinical features and heterogeneity. Therefore, clinical features should be identified to establish a prognosis model for early identification and intervention, thereby improving the clinical prognosis of patients. Objectives The study aimed to investigate the clinical features, risk factors, treatment strategy, and construct a survival prognosis model for anti-MDA5 antibody + DM patients with ILD. Methods A total of 40 anti-MDA5 antibody + DM-ILD patients admitted to the Department of Pulmonary and Critical Care Medicine and the Department of Rheumatology and Immunology in the Second Affiliated Hospital of Xi 'an Jiaotong University from September 2018 to May 2022 were retrospectively analyzed. Prognostic factors correlated with overall survival (OS) during hospitalization were identified by multivariate Cox regression analysis, and a nomogram was established. The nomogram was internally validated using C-index and time-dependent (at 1-, 2-, and 3- months) calibration curves with 1000 iterations of bootstrap resampling. Moreover, the optimal truncation values for continuous variables and Kaplan–Meier (K-M) curves were determined, which were used to analyze the difference in survival between groups. Finally, time-dependent decision curve analysis (DCA) was employed to validate the clinical value of the nomogram. Results Significant differences were found between the survival group and the non-survival group in terms of age, oxygenation index, extent of lung lesions, diffuse alveolar damage (DAD) and nonspecific interstitial pneumonia (NSIP), and LDH, GLU, CEA, ferritin, CRP levels in serum (P < 0.05). Multivariate regression analysis revealed that increased NSIP in high-resolution computed tomography (HRCT) and ALT,LDH,CEA,CRP were risk factors for poor prognosis (P < 0.05). A nomogram diagram was constructed according to the final multiple Cox model to predict the 1-, 2-, and 3-month OS. According to ALT, AST, LDH, CEA, and CRP cutoff values, the KM algorithm was used to estimate the survival curve (P < 0.05). DCA curves were drawn for the model-dependent variables included treatment style, NSIP, ALT, AST, LDH, CEA, and CRP. This indicated that the nomogram yielded a higher net benefit compared to other single prognostic factors, and the cutoff value grouping model showed better practical application value. Combined treatment with glucocorticoids and immunosuppressants was a protective factor for long-term survival. Survival analysis indicated that patients with anti-MDA5 + DM-ILD could benefit from combined treatment for longer survival. Conclusions Anti-MDA5 antibody + DM is prone to interstitial lung disease, poor prognosis, and high mortality. Risk prediction model could help us paying attention to these features which may allow the early identification of high-risk patients and promote timely diagnosis and treatment. Background Several studies have shown that patients with anti-MDA5 antibody-positive dermatomyositis (anti-MDA5 antibody + DM) have an increased risk of developing rapid progression of interstitial lung disease (RPILD), which is associated with poor prognosis and high mortality. However, diagnosis and treatment are often delayed due to atypical early clinical features and heterogeneity. Therefore, clinical features should be identified to establish a prognosis model for early identification and intervention, thereby improving the clinical prognosis of patients. Objectives The study aimed to investigate the clinical features, risk factors, treatment strategy, and construct a survival prognosis model for anti-MDA5 antibody + DM patients with ILD. Methods A total of 40 anti-MDA5 antibody + DM-ILD patients admitted to the Department of Pulmonary and Critical Care Medicine and the Department of Rheumatology and Immunology in the Second Affiliated Hospital of Xi 'an Jiaotong University from September 2018 to May 2022 were retrospectively analyzed. Prognostic factors correlated with overall survival (OS) during hospitalization were identified by multivariate Cox regression analysis, and a nomogram was established. The nomogram was internally validated using C-index and time-dependent (at 1-, 2-, and 3- months) calibration curves with 1000 iterations of bootstrap resampling. Moreover, the optimal truncation values for continuous variables and Kaplan–Meier (K-M) curves were determined, which were used to analyze the difference in survival between groups. Finally, time-dependent decision curve analysis (DCA) was employed to validate the clinical value of the nomogram. Results Significant differences were found between the survival group and the non-survival group in terms of age, oxygenation index, extent of lung lesions, diffuse alveolar damage (DAD) and nonspecific interstitial pneumonia (NSIP), and LDH, GLU, CEA, ferritin, CRP levels in serum ( P < 0.05). Multivariate regression analysis revealed that increased NSIP in high-resolution computed tomography (HRCT) and ALT,LDH,CEA,CRP were risk factors for poor prognosis ( P < 0.05). A nomogram diagram was constructed according to the final multiple Cox model to predict the 1-, 2-, and 3-month OS. According to ALT, AST, LDH, CEA, and CRP cutoff values, the KM algorithm was used to estimate the survival curve ( P < 0.05). DCA curves were drawn for the model-dependent variables included treatment style, NSIP, ALT, AST, LDH, CEA, and CRP. This indicated that the nomogram yielded a higher net benefit compared to other single prognostic factors, and the cutoff value grouping model showed better practical application value. Combined treatment with glucocorticoids and immunosuppressants was a protective factor for long-term survival. Survival analysis indicated that patients with anti-MDA5 + DM-ILD could benefit from combined treatment for longer survival. Conclusions Anti-MDA5 antibody + DM is prone to interstitial lung disease, poor prognosis, and high mortality. Risk prediction model could help us paying attention to these features which may allow the early identification of high-risk patients and promote timely diagnosis and treatment. Several studies have shown that patients with anti-MDA5 antibody-positive dermatomyositis (anti-MDA5 antibody + DM) have an increased risk of developing rapid progression of interstitial lung disease (RPILD), which is associated with poor prognosis and high mortality. However, diagnosis and treatment are often delayed due to atypical early clinical features and heterogeneity. Therefore, clinical features should be identified to establish a prognosis model for early identification and intervention, thereby improving the clinical prognosis of patients. The study aimed to investigate the clinical features, risk factors, treatment strategy, and construct a survival prognosis model for anti-MDA5 antibody + DM patients with ILD. A total of 40 anti-MDA5 antibody + DM-ILD patients admitted to the Department of Pulmonary and Critical Care Medicine and the Department of Rheumatology and Immunology in the Second Affiliated Hospital of Xi 'an Jiaotong University from September 2018 to May 2022 were retrospectively analyzed. Prognostic factors correlated with overall survival (OS) during hospitalization were identified by multivariate Cox regression analysis, and a nomogram was established. The nomogram was internally validated using C-index and time-dependent (at 1-, 2-, and 3- months) calibration curves with 1000 iterations of bootstrap resampling. Moreover, the optimal truncation values for continuous variables and Kaplan-Meier (K-M) curves were determined, which were used to analyze the difference in survival between groups. Finally, time-dependent decision curve analysis (DCA) was employed to validate the clinical value of the nomogram. Significant differences were found between the survival group and the non-survival group in terms of age, oxygenation index, extent of lung lesions, diffuse alveolar damage (DAD) and nonspecific interstitial pneumonia (NSIP), and LDH, GLU, CEA, ferritin, CRP levels in serum (P < 0.05). Multivariate regression analysis revealed that increased NSIP in high-resolution computed tomography (HRCT) and ALT,LDH,CEA,CRP were risk factors for poor prognosis (P < 0.05). A nomogram diagram was constructed according to the final multiple Cox model to predict the 1-, 2-, and 3-month OS. According to ALT, AST, LDH, CEA, and CRP cutoff values, the KM algorithm was used to estimate the survival curve (P < 0.05). DCA curves were drawn for the model-dependent variables included treatment style, NSIP, ALT, AST, LDH, CEA, and CRP. This indicated that the nomogram yielded a higher net benefit compared to other single prognostic factors, and the cutoff value grouping model showed better practical application value. Combined treatment with glucocorticoids and immunosuppressants was a protective factor for long-term survival. Survival analysis indicated that patients with anti-MDA5 + DM-ILD could benefit from combined treatment for longer survival. Anti-MDA5 antibody + DM is prone to interstitial lung disease, poor prognosis, and high mortality. Risk prediction model could help us paying attention to these features which may allow the early identification of high-risk patients and promote timely diagnosis and treatment. |
| Audience | Academic |
| Author | Wang, Chunya Yang, Shuanying Fan, Na Kong, Qunyu Li, Cong Zhao, Kaikai Shi, Jie Li, Xueyi Zhang, Juan Huo, Kaikai Fang, Ping Zhang, Yong Deng, Wenjing |
| Author_xml | – sequence: 1 givenname: Kaikai surname: Zhao fullname: Zhao, Kaikai organization: Department of Pulmonary and Critical Care Medicine, the Second Affiliated Hospital fo Xi’an Jiaotong University – sequence: 2 givenname: Juan surname: Zhang fullname: Zhang, Juan organization: Department of Pulmonary and Critical Care Medicine, the Second Affiliated Hospital fo Xi’an Jiaotong University – sequence: 3 givenname: Qunyu surname: Kong fullname: Kong, Qunyu organization: Chongqing Nanpeng Artificial Intelligence Technology Research Institute Co., Ltd – sequence: 4 givenname: Yong surname: Zhang fullname: Zhang, Yong organization: Chongqing Nanpeng Artificial Intelligence Technology Research Institute Co., Ltd – sequence: 5 givenname: Cong surname: Li fullname: Li, Cong organization: Department of Pulmonary and Critical Care Medicine, the Second Affiliated Hospital fo Xi’an Jiaotong University – sequence: 6 givenname: Kaikai surname: Huo fullname: Huo, Kaikai organization: Department of Pulmonary and Critical Care Medicine, the Second Affiliated Hospital fo Xi’an Jiaotong University – sequence: 7 givenname: Na surname: Fan fullname: Fan, Na organization: Department of Pulmonary and Critical Care Medicine, the Second Affiliated Hospital fo Xi’an Jiaotong University – sequence: 8 givenname: Wenjing surname: Deng fullname: Deng, Wenjing organization: Department of Pulmonary and Critical Care Medicine, the Second Affiliated Hospital fo Xi’an Jiaotong University – sequence: 9 givenname: Jie surname: Shi fullname: Shi, Jie organization: Department of Pulmonary and Critical Care Medicine, the Second Affiliated Hospital fo Xi’an Jiaotong University – sequence: 10 givenname: Chunya surname: Wang fullname: Wang, Chunya organization: Department of Pulmonary and Critical Care Medicine, the Second Affiliated Hospital fo Xi’an Jiaotong University – sequence: 11 givenname: Xueyi surname: Li fullname: Li, Xueyi organization: Department of Pulmonary and Critical Care Medicine, the Second Affiliated Hospital fo Xi’an Jiaotong University – sequence: 12 givenname: Shuanying surname: Yang fullname: Yang, Shuanying organization: Department of Pulmonary and Critical Care Medicine, the Second Affiliated Hospital fo Xi’an Jiaotong University – sequence: 13 givenname: Ping surname: Fang fullname: Fang, Ping email: pingf7613@xjtu.edu.cn organization: Department of Pulmonary and Critical Care Medicine, the Second Affiliated Hospital fo Xi’an Jiaotong University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39948593$$D View this record in MEDLINE/PubMed |
| BookMark | eNptktuKFDEQhhtZcQ_6Al5Igzfe9Jpjd-ZKhvG0sOKNXod0UpnN0J2MSXqW2Xfwnc1Mr4sDEkKKqj9fVch_WZ354KGqXmN0jbFo3ydMUccbRMqmTPDm4Vl1gVknmpa25Owp5uy8ukxpgxAhC8JeVOd0sSj6Bb2ofq8G551WQ21B5SlCqpU3dZrizu1KVnk17JNLdbA1Q7VWCY6x8tk13z4u-THqg9k325BcdjuoDcRR5TDuj4lU6zBuh9Ijg6nvXb6rnc8QUy7F0mGY_Lo2LkFBv6yeWzUkePV4XlU_P3_6sfra3H7_crNa3jaGCZEb4ASYtRwzpi3pWyK04H2rwXJEOaAF7QF1FIFAAtsemQ646qm2YDG3QOlVdTNzTVAbuY1uVHEvg3LymAhxLVXMTg8gW6MsLhhGW8YUE4oYq4WgCve2N9YW1oeZtZ36EYwGn6MaTqCnFe_u5DrsZPlDQglChfDukRDDrwlSlqNLGoZBeQhTkhS3bdcyzg7St7N0rcpszttQkPogl0tBOlZmRKyorv-jKsvA6HQxkXUlf3Lhzb9veBr-r0-KgM6CVEp-DVFuwhSLN5LE6PCSVs5ulMWN8uhG-UD_ALwO1XM |
| ContentType | Journal Article |
| Copyright | The Author(s) 2025 2025. The Author(s). COPYRIGHT 2025 BioMed Central Ltd. The Author(s) 2025 2025 |
| Copyright_xml | – notice: The Author(s) 2025 – notice: 2025. The Author(s). – notice: COPYRIGHT 2025 BioMed Central Ltd. – notice: The Author(s) 2025 2025 |
| DBID | C6C CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1186/s13075-025-03485-z |
| DatabaseName | Springer Nature OA Free Journals Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1478-6362 |
| EndPage | 14 |
| ExternalDocumentID | oai_doaj_org_article_6daf108143644a48a2dfc883a1bfbdff PMC11823200 A827464404 39948593 10_1186_s13075_025_03485_z |
| Genre | Journal Article |
| GeographicLocations | Japan |
| GeographicLocations_xml | – name: Japan |
| GroupedDBID | --- .GJ 0R~ 23N 2WC 4.4 5GY 5VS 6J9 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML ABUWG ACGFS ACJQM ADBBV ADUKV AEGXH AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK E3Z EBD EBLON EMOBN F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE HZ~ INH INR ITC KQ8 M1P O5R O5S O9- PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ ROL RPM RSV SMD SOJ SV3 TR2 U2A UKHRP WOQ ALIPV CGR CUY CVF ECM EIF NPM AFFHD 7X8 5PM |
| ID | FETCH-LOGICAL-d488t-e52e4ff5144cf2b628c85b6cef5035e093be0730e8081fb0d7e5ab3cfef15fe33 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 2 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001421566600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1478-6354 1478-6362 |
| IngestDate | Mon Nov 10 04:33:17 EST 2025 Tue Nov 04 02:06:27 EST 2025 Fri Sep 05 08:26:55 EDT 2025 Sat Nov 29 13:51:52 EST 2025 Sat Nov 29 10:33:42 EST 2025 Fri May 09 01:30:38 EDT 2025 Sat Sep 06 07:29:06 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Anti-MDA5 antibody Interstitial lung disease Prognostic factors Dermatomyositis |
| Language | English |
| License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-d488t-e52e4ff5144cf2b628c85b6cef5035e093be0730e8081fb0d7e5ab3cfef15fe33 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://link.springer.com/10.1186/s13075-025-03485-z |
| PMID | 39948593 |
| PQID | 3166764540 |
| PQPubID | 23479 |
| PageCount | 14 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_6daf108143644a48a2dfc883a1bfbdff pubmedcentral_primary_oai_pubmedcentral_nih_gov_11823200 proquest_miscellaneous_3166764540 gale_infotracmisc_A827464404 gale_infotracacademiconefile_A827464404 pubmed_primary_39948593 springer_journals_10_1186_s13075_025_03485_z |
| PublicationCentury | 2000 |
| PublicationDate | 2025-02-13 |
| PublicationDateYYYYMMDD | 2025-02-13 |
| PublicationDate_xml | – month: 02 year: 2025 text: 2025-02-13 day: 13 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Arthritis research & therapy |
| PublicationTitleAbbrev | Arthritis Res Ther |
| PublicationTitleAlternate | Arthritis Res Ther |
| PublicationYear | 2025 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| SSID | ssj0022924 |
| Score | 2.462614 |
| Snippet | Background
Several studies have shown that patients with anti-MDA5 antibody-positive dermatomyositis (anti-MDA5 antibody + DM) have an increased risk of... Several studies have shown that patients with anti-MDA5 antibody-positive dermatomyositis (anti-MDA5 antibody + DM) have an increased risk of developing rapid... Background Several studies have shown that patients with anti-MDA5 antibody-positive dermatomyositis (anti-MDA5 antibody + DM) have an increased risk of... Several studies have shown that patients with anti-MDA5 antibody-positive dermatomyositis (anti-MDA5 antibody + DM) have an increased risk of developing rapid... Abstract Background Several studies have shown that patients with anti-MDA5 antibody-positive dermatomyositis (anti-MDA5 antibody + DM) have an increased risk... |
| SourceID | doaj pubmedcentral proquest gale pubmed springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 32 |
| SubjectTerms | Adult Aged Anti-MDA5 antibody Antibodies Autoantibodies - blood Autoantibodies - immunology Biological products Care and treatment Complications and side effects Dermatomyositis Dermatomyositis - complications Dermatomyositis - immunology Dermatomyositis - mortality Development and progression Diagnosis Dosage and administration Event history analysis Female Ferritin Genetic aspects Health aspects Humans Immunosuppressive agents Interferon-Induced Helicase, IFIH1 - immunology Interstitial lung disease Lung diseases Lung diseases, Interstitial Lung Diseases, Interstitial - complications Lung Diseases, Interstitial - immunology Lung Diseases, Interstitial - mortality Male Medical research Medicine Medicine & Public Health Medicine, Experimental Methods Middle Aged Mortality Nomograms Orthopedics Prognosis Prognostic factors Retrospective Studies Rheumatology Risk Factors Survival Analysis Viral antibodies |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQhRAXxJtAQUZC4oLVJHYS57g8Ki6tOIDUm-XHWFQqSbXZrdT-B_4zM463asqBC4dISZyD1_PNN571-DNj75D0vbLWidBCI5Que-Fa6YSrvC-7UEcPMR020R0f65OT_tuNo76oJmyWB54H7qANNlYYt5TEyG2VtnWIXmtpKxddiJHYt-z6XTKVU60a04rdFhndHkzI1B3tRMZLKt2IqyzR_zcR34hEt6skby2Vpgh0-JA9yFNHvpq7_IjdgeExu3eUF8efsN9Z4_OMR0hynRO3Q-DTFtkA8YQPs_4IHyNXJfcYv9I9ju2pOPq8atKdG8OlmEu5LoAHIu7N-OsyvZj4dQU6BE5_4XKSm1hTvQHimJ8hc_C85POU_Tj88v3TV5FPWxABnXgjoKlBxYgTKOVj7dpae924Fm3VlLKBspcOiA-AzuqIrgwdNNZJHyFWTQQpn7G9YRzgBcO-Qed6B630QfWq6W2luxqJFGyF3-uCfaTBN-ezoIYhiev0Ag1vsuHNvwxfsPdkOkOOiPbxNu8nwC6QpJVZaUy4W5I_LNj-4kt0IL9ofrszvqEmqjobYNxORlZUAUwahQV7PoPhus84sVOkFVcwvYDJ4kctW4bTn0m_m3I6iexUsA87RJnMHJNJSZluzQxZg5A1CbLm6uX_GLVX7H6d3KAWldxne5v1Fl6zu_4CMbR-k5zoD5aPJ6E priority: 102 providerName: Directory of Open Access Journals |
| Title | Clinical features and survival analysis of 40 cases of anti-MDA5 antibody-positive dermatomyositis complicated with interstitial lung disease |
| URI | https://link.springer.com/article/10.1186/s13075-025-03485-z https://www.ncbi.nlm.nih.gov/pubmed/39948593 https://www.proquest.com/docview/3166764540 https://pubmed.ncbi.nlm.nih.gov/PMC11823200 https://doaj.org/article/6daf108143644a48a2dfc883a1bfbdff |
| Volume | 27 |
| WOSCitedRecordID | wos001421566600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1478-6362 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0022924 issn: 1478-6354 databaseCode: RBZ dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1478-6362 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0022924 issn: 1478-6354 databaseCode: DOA dateStart: 19990101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVPQU databaseName: Health & Medicine (ProQuest) customDbUrl: eissn: 1478-6362 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0022924 issn: 1478-6354 databaseCode: 7X7 dateStart: 20150101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1478-6362 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0022924 issn: 1478-6354 databaseCode: BENPR dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1478-6362 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0022924 issn: 1478-6354 databaseCode: PIMPY dateStart: 20150101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1478-6362 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0022924 issn: 1478-6354 databaseCode: RSV dateStart: 19990601 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFD5iG0J74c4IjMpISLxgkcRO4jx2sAkeWlXjovJk-QqTRoKadtL2H_jPHDtpRQcv8JAoiR3V1fnOZ5_4-DPACyR9w5XS1JauoFykNdUl01RnxqSVzb1xPm42UU2nYj6vZ8OisG6d7b6ekoxMHd1alK87ZNsqrCbGg3FR0Ksd2MPuToQNG04_fN6EWTmGFOvlMX99b5Dn_5OEf-uFrmdIXpsmjb3PyZ3_a_dduD2MNsm4h8c9uOGa-3BrMsynP4CfgyzoOfEuKnx2RDWWdCskEIQg3vSSJaT1hKfEYJcXr9EcZ3TydlzEK93aS9pnf104YgPXL9vvl_FBRzZJ686S8NWXBIWKRUhRQOiTcyQbMswSPYRPJ8cf37yjwwYN1KLfL6krcse9xzEXNz7XZS6MKHSJ5i1SVri0ZtoFCnFhew-vU1u5QmlmvPNZ4R1jj2C3aRv3GLBtrtK1diUzlte8qFUmqhy516kM64sEjoLN5I9eg0MGVez4oF18lYOTydIqn-FPcYajPMWFyq03QjCVaa-t9wm8DBaXwXfRrEYNSxCwCUEFS44FxuhlUExM4HCrJvqc2Sp-vsaMDEUhUa1x7aqTLAtJw0HWMIGDHkObNuNYkAd5uQTEFrq2_tR2SXP2LUp-hzCQIaEl8GoNMjmQTSdjHCdK2SNNItJkRJq8evJv1Z_Cfh5xmtOMHcLucrFyz-CmuUC0LEawU82reBYj2Ds6ns5OR_ETBt7N3k9mX0bRD38BOtAxgw |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFLWgIGDD-xEoYCQkNlhNYjtxlsOjKqIzQlBQd5afUKkkaDJTqf0H_plrxxmRwgYWkZLYURzdc4994-tjhJ4D6RumlCa2cpwwkTdEV1QTXRiT17b0xvm42US9WIjDw-ZDWhTWj9nu45RkZOro1qLa6YFt67CaGA7KBCdnF9ElBj1WUMz_-OnLJswqIaQYl8f89bkkz_8nCf_WC53PkDw3TRp7n90b_9fum-h6Gm3i2QCPW-iCa2-jK_M0n34H_UyyoMfYu6jw2WPVWtyvgUAAgnAxSJbgzmOWYwNdXjwHcxyR-ZsZj2e6s6dkyP46cdgGrl9130_jjR5vktadxeGvLw4KFcuQogDQx8dANjjNEt1Fn3ffHrzeI2mDBmLB71fE8dIx72HMxYwvdVUKI7iuwLw8p9zlDdUuUIgL23t4ndvacaWp8c4X3DtK76GttmvdAwRtc7VutKuosaxhvFGFqEvgXqcKqC8y9CrYTP4YNDhkUMWON7rlV5mcTFZW-QJexSiM8hQTqrTeCEFVob223mfoRbC4DL4LZjUqLUGAJgQVLDkTEKNXQTExQ9uTmuBzZlL8bMSMDEUhUa113bqXtAhJw0HWMEP3Bwxt2gxjQRbk5TIkJuiafNS0pD36FiW_QxhIgdAy9HIEmUxk08sYx4lKDkiTgDQZkSbPHv5b9afo6t7BfF_uv1u8f4SulRGzJSnoNtpaLdfuMbpsTgA5yyfR434BJjEuVw |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagoIoL70eggJGQuGA1ie3EOS6UFQi6qsRDvVl-QqWSVJvdSu1_4D8z42RX3cIFcVgpGzuSo_nmsyee-UzISyB9J4yxzFdBMqHyhtmKW2YL5_Lal9GFmA6bqGczdXjYHFyo4k_Z7qstyaGmAVWa2sXuiY-Di6tqtwfmrbGyGH5cKMnOr5JrAhPpMV7__G0dcpUQXqxKZf763CjV_ychX5iRLmdLXtoyTTPR9Nb_v8NtcnNchdLJAJs75Epo75Lt_XGf_R75NcqFHtMYkvJnT03rab8EYgFowp9ByoR2kYqcOpgK0zWY6Yjt701kurKdP2NDVthpoB7ngEX38yzd6Ok6mT14il-DKSpXzDF1AVyCHgMJ0XH36D75On335e17Nh7cwDzwwYIFWQYRI6zFhIulrUrllLQVmF3mXIa84TYgtQQ89iPa3NdBGstdDLGQMXD-gGy1XRseERhbqG1jQ8WdF42QjSlUXQInB1NAf5WRN2g_fTJoc2hUy043uvl3PTqfrryJAA5YGsLqzwhlSh-dUtwUNlofY0ZeofU1-jSY2JmxNAGGgOpYeqIgdq9QSTEjOxs9wRfdRvOLFX40NmECWxu6Za95gcnEKHeYkYcDntZjhjWiQNm5jKgNpG281GZLe_QjSYFjeMiB6DLyegU4PZJQr1N8pyo9IE0D0nRCmj5__G_dn5Ptg72p_vRh9vEJuVEmyJas4DtkazFfhqfkujsF4MyfJef7Da98Nzs |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+features+and+survival+analysis+of+40+cases+of+anti-MDA5+antibody-positive+dermatomyositis+complicated+with+interstitial+lung+disease&rft.jtitle=Arthritis+research+%26+therapy&rft.au=Zhao%2C+Kaikai&rft.au=Zhang%2C+Juan&rft.au=Kong%2C+Qunyu&rft.au=Zhang%2C+Yong&rft.date=2025-02-13&rft.pub=BioMed+Central&rft.eissn=1478-6362&rft.volume=27&rft.issue=1&rft_id=info:doi/10.1186%2Fs13075-025-03485-z&rft.externalDocID=10_1186_s13075_025_03485_z |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-6354&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-6354&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-6354&client=summon |